Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study


Correspondence: Keji Xie, Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.




  • To compare the efficacy and safety of transurethral enucleation and resection of the prostate (TUERP) and transvesical prostatectomy (TVP) for patients with benign prostatic hyperplasia (BPH) and prostate volumes >80 mL.

Patients and Methods

  • A total of 100 patients with urodynamic obstruction and prostate volume >80 mL were prospectively randomized and enrolled in the study at a tertiary hospital.
  • Patients underwent TVP or TUERP performed by one of two surgeons with experience of a large number of cases.
  • All patients were preoperatively evaluated using patient age, prostate volume measurement, clinical characteristics of digital rectal examination, self-assessment using the International Prostate Symptom Scores (IPSS) questionnaire, a quality-of-life (QoL) questionnaire, maximum urinary flow rate (Qmax), post-void residual urine volume (PVR), urine analysis, blood sample analysis, including determination of prostate-specific antigen (PSA) and haemoglobin concentration.
  • All patients were assessed peri-operatively and postoperatively at 3 and 12 months. All complications were documented.


  • Of 100 patients eligible to participate, 92 patients completed 12 months of follow-up.
  • Patients who underwent TUERP had shorter catheterization times and hospital stays. Operation duration was not significantly different between the two surgical groups (P = 0.107).
  • The resected adenoma weight in the TVP group was more than that in the TUERP group, but the difference was not significant (P = 0.062).
  • There were no significant differences in IPSS, PVR, Qmax or QoL scores between the groups at 3 and 12 months. The patients in the TVP group appeared to have a better Qmax at 3 months, however, the difference was not significant (P = 0.081).
  • Adverse events were similar in the two groups.


  • We found that TUERP had efficacy and safety equivalent to that of TVP for patients with BPH and prostate volume >80 mL.